Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...3839404142434445464748...123124»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Jemperli (dostarlimab) / GSK, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal:  Immunotherapy in oncogynaecology (Pubmed Central) -  Feb 9, 2023   
    Regarding endometrial cancers, while single-agent immunotherapies have shown very limited activity in an unselected population, dostarlimab and pembrolizumab have been associated with remarkable antitumor activity in case of microsatellite instability (dMMR/MSI), detected in around 30% of patients. Finally, in endometrial cancer that has progressed after first-line chemotherapy, the association of pembrolizumab with an oral antiangiogenic kinase inhibitor (lenvatinib) has demonstrated its superiority over second-line chemotherapy regimens, regardless molecular subgroups, and has become the new standard of care in this indication.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus (clinicaltrials.gov) -  Feb 8, 2023   
    P2,  N=30, Recruiting, 
    Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Jul 2025 --> Jul 2026 Not yet recruiting --> Recruiting
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly, Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal:  Current therapeutic modalities and chemopreventive role of natural products in liver cancer: Progress and promise. (Pubmed Central) -  Feb 7, 2023   
    Drug-induced toxicity is a key obstacle in the treatment of liver cancer, necessitating the development of effective and safe medications, with natural compounds such as resveratrol, curcumin, diallyl sulfide, and others emerging as promising anticancer agents. This review highlights the current status of liver cancer research, signaling pathways, therapeutic targets, current treatment strategies and the chemopreventive role of various natural products in managing liver cancer.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Trial completion date, Trial primary completion date, Monotherapy:  Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients (clinicaltrials.gov) -  Feb 6, 2023   
    P2,  N=16, Recruiting, 
    This review highlights the current status of liver cancer research, signaling pathways, therapeutic targets, current treatment strategies and the chemopreventive role of various natural products in managing liver cancer. Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Epigenetic controller:  Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma. (Pubmed Central) -  Feb 5, 2023   
    Class IIa HDACI and lenvatinib combination therapy induces apoptosis by downregulating FGFR4 and blocking the FGFR signaling in FGFR4-positive HCC cell lines and has demonstrated synergistic antitumor effects and safety. This combination therapy overcomes the problems of conventional therapies and will be beneficial for FGFR4-positive HCC patients.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    MODULE 4: Management of RCC Among Special Patient Populations (San Francisco Marriott Marquis, Yerba Buena Ballroom ) -  Feb 2, 2023 - Abstract #ASCOGU2023ASCO_GU_917;    
    CME Provider and Supporter(s): This event is organized and accredited by Research to Practice and supported through educational grants provided by Aveo Pharmaceuticals, Eisai Inc, Exelixis Inc, and Merck. Incidence and optimal approaches to the management of non-clear cell RCC (eg, papillary, chromophobe) Clinical trial findings (eg, SWOG S1500/PAPMET) documenting the efficacy and safety of available and investigational MET inhibitors for papillary RCC Design, eligibility criteria and published results from the Phase II KEYNOTE-B61 trial evaluating pembrolizumab/lenvatinib as first-line treatment for non-clear cell RCC; implications, if any, for ongoing research and current patient care Proportion of patients with von Hippel-Lindau (VHL)-associated RCC; mechanism of action of belzutifan Key findings from the pivotal Phase II study MK-6482-004 assessing belzutifan for VHL-associated RCC FDA approval of belzutifan for cancers associated with VHL disease and optimal integration of this agent into clinical practice Spectrum, frequency and management of toxicities associated with belzutifan Other novel agents and strategies under clinical development for non-clear cell RCC
  • ||||||||||  MODULE 3: Treatment Options for Relapsed/Refractory RCC (San Francisco Marriott Marquis, Yerba Buena Ballroom ) -  Feb 2, 2023 - Abstract #ASCOGU2023ASCO_GU_916;    
    CME Provider and Supporter(s): This event is organized and accredited by Research to Practice and supported through educational grants provided by Aveo Pharmaceuticals, Eisai Inc, Exelixis Inc, and Merck. Logical sequencing of available therapies for metastatic RCC that has progressed on front-line immunotherapy and/or a TKI; factors affecting decision-making in this setting Published data with and optimal incorporation of VEGF TKI-based strategies (eg, cabozantinib, lenvatinib/everolimus, axitinib) into the care of patients with progressive metastatic RCC Design, entry criteria and major clinical outcomes, including overall survival, from the Phase III TIVO-3 trial comparing tivozanib to sorafenib as third- or fourth-line therapy for RCC FDA approval and optimal incorporation of tivozanib into current management algorithms for patients with relapsed/refractory RCC Role of rechallenge with alternative checkpoint inhibitor-based approaches for disease that has previously progressed on immunotherapy; ongoing studies (eg, TiNivo-2) attempting to evaluate this strategy Available data from cohort 1 of the Phase II LITESPARK-003 study assessing belzutifan/cabozantinib as first-line treatment for advanced RCC; ongoing investigation of belzutifan alone or in combination with other systemic therapies Other promising novel agents and strategies (eg, durvalumab/tremelimumab, savolitinib) under investigation for RCC
  • ||||||||||  MODULE 2: Evidence-Based Selection of First-Line Therapy for Metastatic RCC (San Francisco Marriott Marquis, Yerba Buena Ballroom ) -  Feb 2, 2023 - Abstract #ASCOGU2023ASCO_GU_915;    
    CME Provider and Supporter(s): This event is organized and accredited by Research to Practice and supported through educational grants provided by Aveo Pharmaceuticals, Eisai Inc, Exelixis Inc, and Merck. Key clinical and biologic factors guiding the selection of first-line therapy for patients with newly diagnosed metastatic RCC Published efficacy and safety findings with nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib for treatment-na
  • ||||||||||  AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, PD(L)-1 Biomarker, IO biomarker, Surgery, Metastases:  Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report. (Pubmed Central) -  Feb 2, 2023   
    A combination of lenvatinib and camrelizumab may be a new conversion therapy for initially unresectable HCC to resectable HCC, thus contributing to improve the disease prognosis. In addition, the combination regimen could cause an activated immune response, and LDH, NLR, and CD5+ B-cell levels might be predictors for immunotherapy efficacy.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma. (Pubmed Central) -  Feb 2, 2023   
    Our recommendation is to select appropriate TKIs to treat different types of TC patients, and to prevent and manage drug-related AEs after using TKIs. Our findings indicated that GPX2 plays an important role in lenvatinib-induced HCC cell apoptosis, which might serve as a biomarker for instruction of lenvatinib therapy in HCC patients.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Preclinical, Journal:  Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro. (Pubmed Central) -  Feb 1, 2023   
    Additionally, VC was strongly synergistic with Lenvatinib in inhibition of the proliferative, migratory and invasive capacities of HCC cells in vitro. In conclusion, our results demonstrate that the combination of VC and Lenvatinib has synergistic antitumor activities against HCC cells, providing a promising therapeutic strategy to improve the prognosis of HCC patients.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  The DKK1-CKAP4 signal axis promotes hepatocellular carcinoma aggressiveness. (Pubmed Central) -  Feb 1, 2023   
    Anti-CKAP4 antibody inhibited HCC growth, and its antitumor effect was clearly enhanced when combined with lenvatinib, a multi-kinase inhibitor. These results indicate that simultaneous expression of DKK1 and CKAP4 is involved in the aggressiveness of HCC, and that the combination of anti-CKAP4 antibody and other therapeutics including lenvatinib may represent a promising strategy for treating advanced HCC.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial initiation date:  Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. (clinicaltrials.gov) -  Feb 1, 2023   
    P1/2,  N=27, Not yet recruiting, 
    These results indicate that simultaneous expression of DKK1 and CKAP4 is involved in the aggressiveness of HCC, and that the combination of anti-CKAP4 antibody and other therapeutics including lenvatinib may represent a promising strategy for treating advanced HCC. Initiation date: Oct 2022 --> Feb 2023